Questions for the Board at the AGM, page-8

For anyone attending tomorrow’s AGM, can I suggest you come prepared with the following questions? They might try to limit each shareholder to a couple of questions, but if we can get answers to the following, it would be a good start.

1. How many of the 650-odd global MSC trials has Cynata approached about its Cymerus technology?
• How many of these are being considered for future proof of concepts.
2. How many large pharmacy firms has Cynata presented to in the last 2 years?
3. What is the current state of play with the MOU with Cellularity?
4. How many large financial institutions have approached Cynata after one of its many company presentations at events like the Rodman & Renshaw Investor Conference?
5. What is the earliest foreseeable time for signing a deal for CLI?
• How many potential partners are we in discussions with?
• What is the earliest time this will commence?
6. As we have completed Proof of Concepts in Heart Attack, Diabetic Wounds, Asthma, and CRS,
• Do we intend on running / taking part in numerous concurrent trials spanning a range of treatments or are we focusing on ph2 GvHD and CLI only for the near future?
• How many distinct different potential partners are we in discussions with for these Proof of Concepts?
7. Where does the board see the company in:
• the next 6 months
• this time next year
• 2 years time.
8. Finally, will the board be considering any further company loans to directors to provide them personal finance for future option exercising?